Panbela Therapeutics, Inc. PBLA
We take great care to ensure that the data presented and summarized in this overview for Panbela Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PBLA
View allLatest Institutional Activity in PBLA
Top Purchases
Top Sells
About PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Insider Transactions at PBLA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2023
|
Goldman Sachs Group Inc > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
72,874
-15.48%
|
$0
$0.71 P/Share
|
|
Sep 12
2023
|
Jeffrey E. Jacob Director |
SELL
Bona fide gift
|
Indirect |
275
-100.0%
|
-
|
|
Jan 30
2023
|
Susan Horvath V.P. of Finance & CFO |
BUY
Open market or private purchase
|
Direct |
4,444
+19.91%
|
-
|
|
Jan 30
2023
|
Jennifer K. Simpson President and CEO |
BUY
Open market or private purchase
|
Direct |
4,444
+36.09%
|
-
|
|
Oct 04
2022
|
Donald Robert Schemel Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+29.3%
|
-
|
|
Oct 04
2022
|
Jeffrey E. Jacob Director |
BUY
Open market or private purchase
|
Direct |
33,000
+10.06%
|
-
|
|
Oct 04
2022
|
Michael T. Cullen Director |
BUY
Open market or private purchase
|
Indirect |
165,000
+30.87%
|
-
|
|
May 25
2021
|
Michael T. Cullen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,316
+1.95%
|
-
|
|
May 25
2021
|
Paul W. Schaffer Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,316
+2.52%
|
-
|
|
May 25
2021
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,316
+29.75%
|
-
|
|
May 25
2021
|
Donald Robert Schemel Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,316
+4.28%
|
-
|
|
May 25
2021
|
Arthur Fratamico Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,316
+30.98%
|
-
|
|
Apr 29
2021
|
Suzanne Gagnon Director |
SELL
Bona fide gift
|
Indirect |
1,000
-100.0%
|
-
|
|
Jan 06
2021
|
Suzanne Gagnon Director |
BUY
Bona fide gift
|
Direct |
3,284
+6.63%
|
-
|
|
Jan 06
2021
|
Suzanne Gagnon Director |
SELL
Bona fide gift
|
Indirect |
7,142
-87.72%
|
-
|
|
Dec 01
2020
|
Arthur Fratamico Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+35.17%
|
-
|
|
Dec 01
2020
|
Donald Robert Schemel Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+3.02%
|
-
|
|
Dec 01
2020
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+32.86%
|
-
|
|
Dec 01
2020
|
Paul W. Schaffer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+1.74%
|
-
|